HCW Biologics (HCWB) Corporate presentation summary

Company overview and strategy

• Focuses on developing transformative fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia.

• Utilizes two proprietary drug discovery platforms: TOBI (Tissue Factor-Based Fusion) and TRBC (T-Cell Receptor B-Chain Constant Region).

• Over 50 novel compounds developed internally, with several selected for clinical development or partnership.

• Commercial-ready fusion compounds available as reagents for immunotherapeutic manufacturing.

• Emphasizes subcutaneous administration for treatments.

Product pipeline and clinical programs

• HCW9206 and HCW9201 are commercial-ready reagents for CAR-T and NK cell manufacturing, enhancing efficacy and reducing costs.

• HCW9302, an IL-2-based immunotherapeutic for Treg expansion, is in Phase 1 for alopecia areata, with broader autoimmune indications planned.

• HCW11-006, a multi-cytokine immune cell stimulator, is licensed to Trimmune Biotech with a Phase 1 trial expected in 2027.

• HCW11-018b, a tetravalent T-cell engager, and HCW11-040, a second-generation immune checkpoint inhibitor, are in IND-enabling stages targeting solid tumors and BPD.

• Projected milestones include multiple clinical readouts and IND filings through 2028.

Leadership and management

• Founder and CEO has a proven track record, including founding and selling Altor BioScience for $1 billion and developing ANKTIVA®.

• Senior management team brings extensive experience in research, manufacturing, business development, finance, and legal affairs.